Abstract: The present invention relates to a surfactant booster for use in high foaming cleaning compositions. In an aspect of the invention, a C6, C7, C8, C9, C10, C11 or C12 linear alcohol in very low amounts is added to increase surface activity, foam and wetting properties of the composition. The alcohol is added in an amount of alcohol to surfactant of about 1:100 to 1:200 and must be linear. In another aspect, the invention relates to novel cleaning compositions such as pot and pan soaking compositions, dishwashing compositions, food and beverage foaming cleaners, vehicle cleaning and the like suitable for use in hard water, which can be solid or liquid. The invention further relates to methods of making these compositions, and to methods employing these compositions.

Abstract: The present invention broadly relates to aqueous cleaning compositions and the use thereof in cleaning soiled surfaces.

Abstract: A solid block or unit dosed detergent composition as described which can be utilized in a variety of applications for cleaning surfaces and objects, removing suspending soils, and rinsing easily. The detergent composition, when exposed to an aqueous solution such as water, dissolves quickly and completely to create the use solution.

Abstract: A viscoelastic, solid-state surfactant composition for textile treatment, containing based on the total weight thereof (i) a total amount of 10% to 70% by weight of at least one surfactant, (ii) a total amount of more than 1% by weight of at least one benzylidene alditol compound of formula (I), and (iii) water, constitutes an easily soluble, aesthetically pleasing and storage-stable form of a solid-state composition for providing surfactant-containing liquors.

Abstract: A detergent or cleaning agent, in particular a cleaning agent for hard surfaces, having at least two phases which are different from one another.

Abstract: The invention relates to stable, anhydrous concentrated formulations in tablet form and methods of making stable, anhydrous concentrated formulation tablets.

Abstract: A method, and related apparatus, for producing beer from any types of grains includes activating phenomena of controlled hydro-dynamic cavitation during all the steps of the process, from mashing to hopping, and possibly after yeast inoculation. The present method and apparatus provide a number of advantages over traditional techniques, for example, avoiding the pre-crushing of the malts or the grains, thereby increasing the efficiency of saccharification and of starch extraction, and avoiding the boiling at equal efficiency of the hopping. Another advantage is the opportunity of causing the concentration of gluten to fall in the final product simply with controlled hydraulic processes through electromechanics, and of possibly extending fermentation.

Abstract: A liquid transport method is disclosed for efficiently producing cell cultures. The liquid transport method of the present disclosure, which is in processing of cells, includes: a) a step in which a container holding a liquid is gripped by a gripping tool of a robot; and b) a step in which the liquid in the container is transported to a collection container by rotating the gripped container. In steps a) and b) the robot operates such as not to pass over a vertical line of an opening of the collection container.

Abstract: A bioreactor is provided that permits engineering of multiple different tissues. The bioreactor has a series of flow paths that permit application of tissue-specific media while simultaneously innervating the various different tissues with a common media. The flow paths for the various medias are designed to prevent mixing of the various media as they simultaneously innervate the tissue.

Abstract: Provided herein is a microphysiological system that may be used in various cell culture applications and biological system studies, that facilitates co-culture, monitoring, and study of functional interactions among different types of cellular and biological materials under various environmental conditions. The system is configured for fast assembly and disassembly, thereby minimizing damage or contamination of the biological materials and environmental conditions inside the system. The system comprises a base, a lid, and a plurality of clamps that are connected to the base and the lid. The base has a recess surface for receiving cell culture support layers. The lid has a stepped surface configured to exert a contact force to a top layer of one or more cell culture support layers during use. The clamp involves an engagement mechanism that generates a contact force allowing for sealing of the cell culture support layers in a manner that minimizes leakage of fluids.

Abstract: This disclosure relates to equipment utilized to manufacture chemical agents, particularly biopharmaceuticals. In some embodiments, reactor systems comprising a mobile carriage assembly; a disposable reaction container removably attached to the carriage assembly; and, a carriage holder into which the mobile carriage assembly may be removably inserted are provided.

Abstract: We have modified a commercially-available adherent cell culture bioreactor in several ways to increase productivity of cultured cells, while decreasing contamination risk. We found that modifying a commercially-available adherent cell culture bioreactor to provide for slower cell culture medium flow unexpectedly and dramatically increases the productivity of the cultured adherent cells. We also developed a new sampling manifold configuration and new way of taking samples, to reduce contamination risk.

Abstract: A bioreaction container including a culture chamber configured to contain a culture solution and a life form in an inner space, the culture chamber having an open upper end; a chamber cover portion coupled to the upper end of the culture chamber, the chamber cover portion having a protruding tube provided on one side thereof so as to communicate with the inner space; a filter cap coupled to the protruding tube in an attachable/detachable manner so as to open/close the protruding tube; a gas introduction portion configured to penetrate the chamber cover portion and to communicate with the inner space so as to supply a predetermined gas into the inner space; and an acidity/basicity adjustment portion installed on the chamber cover portion while containing an adjustment solution that adjusts pH of the culture solution such that the adjustment solution is discharged into the inner space by pneumatic pressure.

Abstract: A method for processing biological material containing stringy tissue in a container having a tissue collector disposed in a tissue retention volume on one side of an internal filter includes washing biological material contained in the tissue retention volume with wash liquid to the tissue retention volume and allowing the wash liquid and rotating the tissue collector disposed in the tissue retention volume relative to the container in a first direction of rotation about an axis of rotation to sweep the teeth positioned on the tissue collector through the biological material and to collect stringy material on the tissue collector.

Abstract: A method for preparing a hyper-cellulolytic catabolite derepressed mutants of ascomycetes fungus, especially variants of Penicillium funiculosum. Selection media used to isolate such variants include amorphous cellulose and a high concentration of glucose. Cellulase activities of mutant ID-10, in particular such as FPase and ?-glucosidase were 1.5 times higher than Penicillium funiculosum MRJ-16 (parent). Furthermore, fungal mutant morphology was changed and no pH adjustment was required throughout the enzyme production process.

Abstract: A novel method of growing fungi is disclosed which uses an engineered artificial media and produces high density filamentous fungi biomats that can be harvested with a minimum of processing and from which fungal products such as antibiotics, proteins, and lipids can be isolated, the method resulting in lowered fungus cultivation costs for energy usage, oxygenation, water usage and waste stream production.

Abstract: Provided is a microorganism of the genus Epidermidibacterium belonging to the family Sporichthyaceae, or a culture thereof, or a composition for preventing, improving, or treating skin conditions or inflammatory diseases including the same.

Abstract: The present invention provides a medium composition containing deacylated gellan gum or a salt thereof, and an acidic polysaccharide or a salt thereof capable of maintaining a random coil state in a divalent metal cation medium and cross-linking via a divalent metal ion, and permitting culture of a cell or a tissue in suspension, wherein a concentration of the deacylated gellan gum or a salt thereof in the medium composition is 0.002-0.01 (w/v) %, a concentration of the acidic polysaccharide or a salt thereof is 0.004-0.1 (w/v) %, and a mass ratio of the acidic polysaccharide or a salt thereof to the deacylated gellan gum or a salt thereof is not less than 1. In addition, the present invention provides a method for isolating a cell or tissue from a culture preparation containing the medium composition and cell or tissue, including applying a shear force to the culture preparation.

Abstract: Described are medical products, methods, and cryogenic bags or other containers suitable for storing and/or transporting and/or processing cellular compositions and other related materials. In certain aspects, the contents of such cryogenic bags may be warmed, mixed, and applied to a patient. Medical products described herein find particular use in treating diseased and/or damaged tissue such as in wound repair and/or bone repair. Related methods of manufacture are also described.

Abstract: Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cell characteristics, such as viability, motility, functionality, fertilization rates, and pregnancy rates. Further, sperm cell characteristics may be addressed within the context of various collection, handling, separation, storage, transportation, usage, fertilization, or insemination techniques.

Abstract: The present invention provides a method for inducing differentiation of pluripotent stem cells into neural precursor cells, comprising culturing the pluripotent stem cells in the presence of a small, molecule BMP inhibitor, and induced neural precursor cells prepared by this method.

Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.

Abstract: A bacteriophage structure, a method of making the structure, and uses of the structure are described. The structure is a substrate with a surface having an ordered arrangement of parallel microridges thereon. Each microridge is composed of a plurality of nanoridges and has a longitudinal axis. Each nanoridge contains a bundle of phage nano fibers having longitudinal axes. The phage nanofibers in each nanoridge bundle are arranged in a substantially smectic alignment. The longitudinal axis of each microridge is perpendicular to the longitudinal axes of the phage nanofibers which make up the nanoridges of the microridge. The structure may be used as a growth surface for inducing differentiation of stem cells such as neural progenitor cells.

Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.

Abstract: This invention relates to an enriched population of isolated and expanded human cord blood stem cells and a method of producing an enriched population of isolated and expanded human cord blood stem cells. The expanded human cord blood stem cells are CD34+, CD90+, CD1 84+, CD1 17+, CD49f+, ALDH+, CD45RA? and express pluripotency genes SOX2, OCT4, NANOG, and ZIC3. In one embodiment, the stem cells in the enriched population of the present invention are positive for aldehyde dehydrogenase activity (ALDH+). In addition, in one embodiment the expanded stem cells are nearly depleted of T cells and B cells and contain a limited number of monocytes (CD14). Also disclosed is a method of treating a subject for a hematological disorder using the stem cells of the present invention and a method of determining the effects of a compound on hematopoietic stem cells.

Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE).

Abstract: Disclosed is a method of manufacturing a medium composition for cell culture, and a method of manufacturing a crushed stem cell extract using a method of manufacturing a medium composition for cell culture and a 3-low extracting method of active ingredients of a stem cell. The medium composition for cell culture includes a basal medium; a hyaluronic acid; and an additive composition. According to an embodiment, when active ingredients of a stem cell are extracted, a stem cell is crushed at a 3-low circumstance of low temperature, low pressure, a hypotonic circumstance.

Abstract: The present invention provides a method of treating a disorder using a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises administering locally to a human being the FReP cell to a site in need thereof of the human being.

Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Abstract: The present disclosure refers to an endonuclease-based gene editing construct, wherein the construct comprises a CRISPR-associated endonuclease (such as Cas9 or Cpf1) or a derivative thereof and at least one or more hormone binding domains of the estrogen receptor (ERT2) or derivatives thereof. The present disclosure also describes a method of editing a genome of a host cell using the construct as disclosed herein, the method comprising transfecting the host cell with the nucleic acid sequence as defined herein and incubating the cell with an inducing agent.

Abstract: Provided is a mutant ?-glucosidase capable of more efficiently saccharifying biomass. A mutant ?-glucosidase comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1, wherein the amino acid sequence has asparagine at one or more positions selected from the group consisting of positions corresponding to positions 787, 790, and 797 of SEQ ID NO: 1, and has ?-glucosidase activity.

Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.

Abstract: Described are mevalonate diphosphate decarboxylase variants having improved activity in converting 3-phosphonoxyisovalerate into isobutene. Such variants can be employed in processes for biologically producing isobutene from 3-hydroxyisovalerate or from 3-hydroxy-3-methylbutyrate into isobutene, for biologically producing isoprenol from mevalonate or from mevalonate-3-phosphate or for biologically producing 1,3-butadiene from 3-hydroxypent-4-enoate or from 3-phosphonoxypent-4-enoate. Also described is an enzyme which is characterized in that it is capable of converting 3-phosphonoxyisovalerate into isobutene with a kcat of more than 0.1 s?1.

Abstract: A nucleic acid construct is provided that encodes two or more or a plurality of spacer sequences separated by restriction endonuclease recognition site. A plurality of such nucleic acid sequences are provided as a library for making guide RNAs for use with CRISPR/Cas systems.

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.

Abstract: The invention provides improved gene therapy vectors, compositions, and methods.

Abstract: This invention provides a method for the in vivo delivery of oligonucleotides. The invention utilizes the presence of one or plurality of HES linked to an oligonucleotide to deliver a nucleic acid sequence of interest into the cytoplasm of cells and tissues of live organisms. The delivery vehicle is nontoxic to cells and organisms. Since delivery is sequence-independent and crosses membranes in a receptor-independent manner, the delivered oligonucleotide can target complementary sequences in the cytoplasm as well as in the nucleus of live cells. Sequences of bacterial or viral origin can also be targeted. The method can be used for delivery of genes coding for expression of specific proteins, antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs or any nucleic acid sequence in a living organism. The latter include mammals, plants, and microorganisms such as bacteria, protozoa, and viruses.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.

Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurogenetic disorder. Such symptoms and hallmarks include developmental delays, ataxia, speech impairment, sleep problems, seizures, and EEG abnormalities. Such neurogenetic disorders include Angelman Syndrome.

Abstract: The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

Abstract: Provided are peptide nucleic acid derivatives targeting a 3? splice site of the human SNAP25 pre-mRNA. The peptide nucleic acid derivatives potently induce at least a splice variant of the human SNAP25 mRNA in cells, and are useful to safely treat dermatological indications or conditions involving the expression of the human SNAP25 protein by topical administration.

Abstract: Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.

Abstract: Provided is a recombinant cell that produces isoprene or terpene, wherein the recombinant cell includes an ability to synthesize isopentenyl diphosphate through a mevalonate pathway (MVA pathway), wherein the recombinant cell lacks an ability to synthesize isopentenyl diphosphate through an endogenous non-mevalonate pathway (MEP pathway), wherein the recombinant cell includes an isoprene synthase gene or a terpene synthase gene as a foreign gene, and wherein the recombinant cell produces, with the expression of the foreign gene, isoprene or terpene having 10, 15, 20, 30, or 40 carbon atoms. The mevalonate pathway is preferably an exogenous mevalonate pathway.

Abstract: This invention relates to the use of CRISPR nucleic acids to screen for essential and non-essential genes and expendable genomic islands in bacteria, archaea, algae and/or yeast, to kill bacteria, archaea, algae and/or yeast, to identify the phenotype of a gene or genes, and/or to screen for reduced genome size and/or a gene deletion in bacteria, archaea, algae and/or yeast.

Abstract: The present invention relates to the culture and manipulation of microorganisms for biotech applications, and is based on the discovery and characterization of spliced leader sequences identified in transcripts from Nannochloropsis species. In particular, the invention provides nucleic acid compositions comprising a SL sequence operably linked to a protein-encoding gene. Further provided are compositions and methods for enhanced gene expression in recombinant microorganisms as well as methods for identification and/or isolation of nucleic acid molecules tagged with a spliced leader sequence.

Abstract: Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human ApoE protein. In some embodiments the polypeptide comprises ApoE2. In some embodiments the polypeptide comprises ApoE3. In some embodiments the polypeptide comprises ApoE4. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress Apo-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease. Also disclosed are methods of screening yeast cells to identify genetic suppressors or enhancers of ApoE-induced toxicity. Also disclosed are genetic suppressors or enhancers of ApoE-induced toxicity identified using the methods, and human homologs thereof. Also disclosed are methods of identifying compounds that modulate expression or activity of genetic modifiers of ApoE-induced toxicity.

Abstract: The present invention relates to a method for introducing a polynucleotide into non-adhesively growing plant cells, comprising the following steps: providing a solid support having immobilized thereto the polynucleotide in dry state; contacting the plant cells with the polynucleotide on the solid support so as to obtain transformed plant cells; and optionally washing the plant cells.

Abstract: The present invention provides plant virus vectors developed from the Sugarcane mosaic virus (SCMV). The vectors include a nucleic acid sequence encoding an infectious Sugarcane mosaic virus (SCMV) operably linked to one or more regulatory elements functional in a plant. The plant virus vectors may be used to infect monocot plants, such as maize, for gene expression applications.